| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Andrew J Montgomery, Anne R Lingford-Hughes, Alice Egerton, David J Nutt, Paul M Grasb. The effect of nicotine on striatal dopamine release in man: A [11C]raclopride PET study. Synapse (New York, N.Y.). vol 61. issue 8. 2007-09-12. PMID:17492764. |
in common with many addictive substances and behaviors nicotine activates the mesolimbic dopaminergic system. |
2007-09-12 |
2023-08-12 |
Not clear |
| Riju Ray, Robert A Schnoll, Caryn Lerma. Pharmacogenetics and smoking cessation with nicotine replacement therapy. CNS drugs. vol 21. issue 7. 2007-09-06. PMID:17579497. |
initial findings suggest that polymorphisms in nicotine metabolising enzymes, and selected genes in the dopaminergic and opioidergic pathways, may have predictive validity for nrt response; however, independent replication is necessary before translation to clinical practice. |
2007-09-06 |
2023-08-12 |
Not clear |
| Raad Nashmi, Cheng Xiao, Purnima Deshpande, Sheri McKinney, Sharon R Grady, Paul Whiteaker, Qi Huang, Tristan McClure-Begley, Jon M Lindstrom, Cesar Labarca, Allan C Collins, Michael J Marks, Henry A Leste. Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 27. issue 31. 2007-08-28. PMID:17670967. |
although the midbrain dopaminergic system dominates reward pathways, chronic nicotine does not change alpha4* receptor levels in dopaminergic neurons of ventral tegmental area (vta) or substantia nigra pars compacta. |
2007-08-28 |
2023-08-12 |
mouse |
| Raad Nashmi, Cheng Xiao, Purnima Deshpande, Sheri McKinney, Sharon R Grady, Paul Whiteaker, Qi Huang, Tristan McClure-Begley, Jon M Lindstrom, Cesar Labarca, Allan C Collins, Michael J Marks, Henry A Leste. Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 27. issue 31. 2007-08-28. PMID:17670967. |
in consequence, gabaergic neurons from chronically nicotine-treated mice have a higher basal firing rate and respond more strongly to nicotine; because of the resulting increased inhibition, dopaminergic neurons have lower basal firing and decreased response to nicotine. |
2007-08-28 |
2023-08-12 |
mouse |
| Nimish Sidhpura, Peter Redfern, Susan Wonnacot. Comparison of the effects of bupropion on nicotinic receptor-evoked [(3)H]dopamine release from rat striatal synaptosomes and slices. European journal of pharmacology. vol 567. issue 1-2. 2007-07-27. PMID:17477919. |
tobacco smoking is a nicotine addiction, mediated in part by the ability of nicotine to elicit dopamine release, as a result of the stimulation of nicotinic acetylcholine receptors associated with dopaminergic pathways. |
2007-07-27 |
2023-08-12 |
rat |
| Joke Beuten, Jennie Z Ma, Xiang-Yang Lou, Thomas J Payne, Ming D L. Association analysis of the protein phosphatase 1 regulatory subunit 1B (PPP1R1B) gene with nicotine dependence in European- and African-American smokers. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. vol 144B. issue 3. 2007-07-18. PMID:17171661. |
because the mesolimbic dopaminergic system is implicated in the reinforcing effects of many drugs, including nicotine, ppp1r1b is considered a plausible candidate for involvement in the development of vulnerability to nicotine dependence (nd). |
2007-07-18 |
2023-08-12 |
Not clear |
| Vincenzo Di Matteo, Massimo Pierucci, Giuseppe Di Giovanni, Arcangelo Benigno, Ennio Esposit. The neurobiological bases for the pharmacotherapy of nicotine addiction. Current pharmaceutical design. vol 13. issue 12. 2007-07-09. PMID:17504235. |
a large body of evidence indicates that the locomotor activation and the reinforcing effects of nicotine may be related to its stimulatory effects on the mesolimbic dopaminergic function. |
2007-07-09 |
2023-08-12 |
Not clear |
| Vincenzo Di Matteo, Massimo Pierucci, Giuseppe Di Giovanni, Arcangelo Benigno, Ennio Esposit. The neurobiological bases for the pharmacotherapy of nicotine addiction. Current pharmaceutical design. vol 13. issue 12. 2007-07-09. PMID:17504235. |
several lines of evidence indicate that the reinforcing properties of drugs of abuse, including nicotine, can be affected by a number of transmitter systems which may act by modulating central dopaminergic function. |
2007-07-09 |
2023-08-12 |
Not clear |
| Sanna Janhunen, Liisa Ahte. Differential nicotinic regulation of the nigrostriatal and mesolimbic dopaminergic pathways: implications for drug development. Neuroscience and biobehavioral reviews. vol 31. issue 3. 2007-06-28. PMID:17141870. |
comparison of nicotine and epibatidine, two nachr agonists whose relative affinities for various nachr subtypes differ, revealed differences in the nachr-mediated regulation of dopaminergic activation between these dopamine systems. |
2007-06-28 |
2023-08-12 |
Not clear |
| John R Hughe. Effects of abstinence from tobacco: etiology, animal models, epidemiology, and significance: a subjective review. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. vol 9. issue 3. 2007-06-05. PMID:17365765. |
the most validated etiological model suggests that withdrawal is related to decreased dopaminergic activity, but how this relates to nicotine receptor changes is unclear. |
2007-06-05 |
2023-08-12 |
Not clear |
| N Hamdani, J Ades, P Gorwoo. [Heritability and candidate genes in tobacco use]. L'Encephale. vol 32. issue 6 Pt 1. 2007-05-18. PMID:17372541. |
because of the brain reward effects of nicotine on the mesolimbic system, the genes involved in the dopaminergic transmission receive specific attention. |
2007-05-18 |
2023-08-12 |
human |
| Lucyna Antkiewicz-Michaluk, Jerzy Michaluk, Irena Romańska, Piotr Popik, Martyna Krawczyk, Irena Nalepa, Jerzy Vetulan. Nicotine potentiates imipramine-induced effects on catecholamine metabolism: possible relation to antidepressant activity. Pharmacological reports : PR. vol 58. issue 6. 2007-05-11. PMID:17220541. |
as revealed by hplc, dopamine metabolism in the nucleus accumbens was slightly decreased after 14 days of treatment with imipramine, and co-administration of nicotine resulted in a significant and much more pronounced depression of dopamine metabolism in all investigated dopaminergic structures. |
2007-05-11 |
2023-08-12 |
rat |
| Sakura Nakauchi, Yoshihiko Yamazaki, Katumi Sumikaw. Chronic nicotine exposure affects the normal operation of hippocampal circuits. Neuroreport. vol 18. issue 1. 2007-04-05. PMID:17259867. |
in addition, the dopaminergic modulation of temporoammonic synaptic transmission decreased after chronic nicotine treatment. |
2007-04-05 |
2023-08-12 |
Not clear |
| Mirium Khwaja, Alison McCormack, J Michael McIntosh, Donato A Di Monte, Maryka Qui. Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs. Journal of neurochemistry. vol 100. issue 1. 2007-02-22. PMID:17227438. |
the results show that nicotine treatment partially protects against paraquat-induced declines in nigrostriatal dopaminergic neurons to which a select population of alpha6beta2* nachrs are localized. |
2007-02-22 |
2023-08-12 |
mouse |
| Björn Schilström, Vladimir B Ivanov, Charlotte Wiker, Torgny H Svensso. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 32. issue 1. 2007-02-09. PMID:16641937. |
we have previously shown that nicotine, through stimulation of nachrs in the ventral tegmental area (vta), activates midbrain dopamine neurons and, hence, potentiation of these receptors could be an additional mechanism by which galantamine can activate dopaminergic pathways. |
2007-02-09 |
2023-08-12 |
rat |
| Aracy Pereira Silveira Balbani, Jair Cortez Montovan. Methods for smoking cessation and treatment of nicotine dependence. Brazilian journal of otorhinolaryngology. vol 71. issue 6. 2007-02-08. PMID:16878254. |
nicotine induces tolerance and addiction by acting on the central dopaminergic pathways, thus leading to pleasure and reward sensations within the limbic system. |
2007-02-08 |
2023-08-12 |
Not clear |
| K Michael Cummings, Martin Mahone. Current and emerging treatment approaches for tobacco dependence. Current oncology reports. vol 8. issue 6. 2007-02-06. PMID:17040625. |
nicotine creates dependence by activating the dopaminergic reward system in the brain. |
2007-02-06 |
2023-08-12 |
Not clear |
| Taku Nagai, Mina Ito, Noritaka Nakamichi, Hiroyuki Mizoguchi, Hiroyuki Kamei, Ayumi Fukakusa, Toshitaka Nabeshima, Kazuhiro Takuma, Kiyofumi Yamad. The rewards of nicotine: regulation by tissue plasminogen activator-plasmin system through protease activated receptor-1. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 26. issue 47. 2006-12-15. PMID:17122062. |
mesolimbic dopaminergic neurons mediate the rewarding effects of abused drugs, including nicotine. |
2006-12-15 |
2023-08-12 |
mouse |
| Maryka Quik, Neeraja Parameswaran, Sarah E McCallum, Tanuja Bordia, Shanshan Bao, Alison McCormack, Amy Kim, Rachel F Tyndale, J William Langston, Donato A Di Mont. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. Journal of neurochemistry. vol 98. issue 6. 2006-11-07. PMID:16882311. |
animals were then lesioned with low doses of the dopaminergic neurotoxin mptp for several months while nicotine was continued. |
2006-11-07 |
2023-08-12 |
monkey |
| Maryka Quik, Neeraja Parameswaran, Sarah E McCallum, Tanuja Bordia, Shanshan Bao, Alison McCormack, Amy Kim, Rachel F Tyndale, J William Langston, Donato A Di Mont. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. Journal of neurochemistry. vol 98. issue 6. 2006-11-07. PMID:16882311. |
mptp-induced cell loss in the substantia nigra was unaffected by nicotine treatment, indicating that nicotine acts at the striatal level to restore/maintain dopaminergic function. |
2006-11-07 |
2023-08-12 |
monkey |